Researchers are set to present an AI-powered blood test at ADLM 2025 that promises earlier and more accurate detection of Lyme disease. The new test demonstrates sensitivity and specificity exceeding 90%, a significant improvement over current methods. The AI analyses a panel of 10 proteins, identifying unique immune patterns in individuals. This advancement could drastically improve patient outcomes by enabling prompt treatment and reducing the risk of long-term health complications like fatigue, neurocognitive issues, and arthritis.
The AI-driven approach uses machine learning to interpret complex serological results and clinical symptoms more effectively than traditional methods. The test is relatively inexpensive and compatible with standard laboratory equipment, potentially making it commercially available by the end of 2026. By integrating AI into clinical laboratory medicine, this blood test offers hope for early and effective Lyme disease treatment, addressing a critical unmet need in diagnostics.
InBios International Inc. is also developing a new Lyme diagnostic test, the Lyme Detect™ Multiplex ELISA, which utilises machine-learning guided analysis to determine the status of clinical specimens with results in less than two hours.
